MONTGOMERYVILLE, Pa., Jun 01, 2010 (BUSINESS WIRE) --PhotoMedex, Inc. (Nasdaq: PHMD) announced today the appointment of James
W. Sight and Paul J. Denby to its Board of Directors.
Mr. Sight will serve as Vice Chairman of the Board of PhotoMedex. Mr.
Sight, an investor serving on the board of directors of various other
public companies, has over 20 years of experience in corporate
restructurings and financings. He currently serves in the office of the
President of Feldman Mall Properties, Inc., a real estate investment
trust formerly listed on the New York Stock Exchange.
Mr. Denby has over 30 years of experience, through Denby Enterprises,
Inc., in the professional hair care industry. He has represented over
100 companies covering a gamut of professional appliances, cosmetics,
and skincare products. Mr. Denby has served some of the largest beauty
companies in the industry, in such capacities as: sales manager and
direct agent in marketing, merchandising, positioning and promoting
Messrs. Sight and Denby participated in the private and public equity
raises for PhotoMedex over the last 7 months. Between them, they hold
13.7% of the Company's outstanding shares.
Dennis McGrath, PhotoMedex's CEO, said, "The Board unanimously and
enthusiastically concurs that Jim Sight and Paul Denby are excellent
additions, bringing a wealth of experience and insight to the Board."
PhotoMedex is a Global Skin Health Solutions(TM) company that provides
integrated disease management and aesthetic solutions through
complementary laser and light-based devices, pharmaceuticals and
cosmeceuticals. We are a leader in the development, manufacturing and
global marketing of dermatology products and techniques focused on
advancing cost-effective technologies that provide patients with better
outcomes and a higher quality of life. The diseases and conditions we
address include psoriasis, vitiligo, acne, actinic keratosis and sun
damage. Medical devices include the XTRAC(R) Excimer Laser for the
treatment of psoriasis and vitiligo and the Omnilux(TM) non-laser Light
Emitting Diodes (LED) for the treatment of clinical and aesthetic
dermatological conditions including acne, photodamage, skin rejuvenation
and wound healing. PhotoMedex also develops and markets products based
on DNA Repair and its patented, clinically proven Copper Peptide
technology for skin health, hair care and wound care. For more
information, visit www.photomedex.com.
SOURCE: PhotoMedex, Inc.
Dennis McGrath, CEO
Lippert/Heilshorn & Associates, Inc.
Kim Sutton Golodetz, 212-838-3777
Bruce Voss, 310-691-7100